(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Quarter results tomorrow
(bmo 2024-05-06)
Expected move: +/- 8.74%
10.98% $ 1.920
Live Chart Being Loaded With Signals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...
Stats | |
---|---|
Volumen de hoy | 360 645 |
Volumen promedio | 208 873 |
Capitalización de mercado | 94.15M |
EPS | $0 ( 2024-03-26 ) |
Próxima fecha de ganancias | ( $-0.120 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.43 |
ATR14 | $0.0280 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Arcara Jeffrey | Buy | 400 000 | Stock Option (Right to Buy) |
2024-02-02 | Arcara Jeffrey | Buy | 0 | |
2023-12-06 | Miller Richard A Md | Buy | 500 000 | Stock Option (Right to Buy) |
2023-12-06 | Lea Leiv | Buy | 200 000 | Stock Option (Right to Buy) |
2023-12-06 | Jones William Benton | Buy | 200 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 8 310 910 | Sell: 8 757 350 |
Volumen Correlación
Corvus Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
GNLN | 0.95 |
VTGN | 0.947 |
AQST | 0.943 |
LIXT | 0.936 |
OMCL | 0.924 |
FLGC | 0.921 |
BBLG | 0.92 |
NNOX | 0.917 |
NERV | 0.914 |
APTO | 0.914 |
10 Correlaciones Más Negativas | |
---|---|
PRAA | -0.957 |
PEBK | -0.95 |
IEP | -0.931 |
LEXX | -0.928 |
FOXF | -0.927 |
CRWS | -0.916 |
PROV | -0.911 |
FARO | -0.911 |
VORB | -0.91 |
PINC | -0.909 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Corvus Pharmaceuticals Correlación - Moneda/Commodity
Corvus Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-367 000 (0.00 %) |
EPS: | $-1.080 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico